These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20660730)

  • 1. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ultrahigh affinity d-peptide antagonist Of MDM2.
    Zhan C; Zhao L; Wei X; Wu X; Chen X; Yuan W; Lu WY; Pazgier M; Lu W
    J Med Chem; 2012 Jul; 55(13):6237-41. PubMed ID: 22694121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
    Li X; Liu C; Chen S; Hu H; Su J; Zou Y
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
    J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
    Li C; Shen J; Wei X; Xie C; Lu W
    J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
    J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
    Shiheido H; Takashima H; Doi N; Yanagawa H
    PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
    Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
    Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
    Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
    ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics.
    He W; Yan J; Li Y; Yan S; Wang S; Hou P; Lu W
    J Control Release; 2020 Sep; 325():293-303. PubMed ID: 32653500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy.
    Ma B; Niu F; Qu X; He W; Feng C; Wang S; Ouyang Z; Yan J; Wen Y; Xu D; Shao Y; Ma PX; Lu W
    Biomaterials; 2019 Jun; 204():1-12. PubMed ID: 30861422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.